Oxford Immunotec Announces Preliminary Fourth Quarter and Fiscal 2013 Revenue and Initiates 2014 Fiscal Year Guidance
- Preliminary fourth quarter revenue of between $10.1 and $10.5 million, an increase of 91% to 99% over the prior year
- Preliminary 2013 revenue of between $38.6 and $39.0 million, an increase of 87% to 89% over 2012
- 2014 Revenues expected to be in the range of $47 to $50 million